Neurocrine Bioscience diskutieren
Neurocrine Bioscience
WKN: 900964 / Symbol: NBIX / Name: Neurocrine / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
126,90 €
-2,23 %
Buy Neurocrine Bioscience
Sell Neurocrine Bioscience
Buy Neurocrine Bioscience
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Evercore ISI to an "outperform" rating.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Canaccord Genuity Group Inc. from a "hold" rating to a "buy" rating. They now have a $132.00 price target on the stock, up previously from $124.00.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $150.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $146.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $136.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $133.00 to $134.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Wedbush from $120.00 to $137.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Raymond James from $135.00 to $145.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $136.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Stifel Nicolaus from $141.00 to $144.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Barclays PLC from $145.00 to $150.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $134.00 to $153.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neueste Beiträge
Nils1 in Salesforce.com diskutieren